Saturday 17 October 2026
Export RNTX’s income statement to Excel — free account
Rein Therapeutics Inc.
RNTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 64.3% and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.59
0.04
−6.35%
Follow RNTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(229.07%) | 533.38% | 351.84% | (753.55%) | |
| (74.57%) | (115.51%) | (119.66%) | (80.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
10,330.70% | 2,689.91% | 613.49% | (156.76%) | |
Free Cash Flow per Share |
(0.79) | (0.76) | (0.55) | (0.28) | |
Free Cash Flow |
(20.95) | (19.36) | (16.61) | (18.83) | |
| Other line items | |||||
Cash ROIC |
(400.40%) | 77.84% | 57.34% | (37.04%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.36 | 0.39 | 0.33 | 0.38 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.79) | (0.76) | (0.55) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates